Answers are grounded in this paper and cite their sources.
High profile: new activity-based protein profiling (ABPP) probes have been designed that target exclusively monoamine oxidases A and B within living cells (see picture; FAD=flavin adenine dinucleotide, FMN=flavin monodinucleotide). With these probes it could be shown that the MAO inhibitor deprenyl, which is in clinical use against Parkinson's disease, shows unique protein specificity despite its covalent mechanism of action.
No takes yet. Share an insight, caveat, or question.
Krysiak et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: